The next meeting of the AOTMiT Transparency Council is taking place on May 8.
The Transparency Council is meeting today. What's on the agenda?
Published May 8, 2023 10:00
Źródło: AOTMiT
The agenda includes:
Preparation of a position paper on the evaluation of the legitimacy of the qualification of the health care service "Pediatric emergency care" as a guaranteed benefit of hospital treatment.
Preparation of a position paper on the appropriateness of issuing reimbursement approvals for the drug Welireg (belzutifan) for the indications von Hippel-Lindau syndrome (VHL); von Hippel-Lindau syndrome (VHL) for high-risk radiation therapy and surgical treatment of tumors.
Preparation of opinions on recommended medical technologies, activities carried out within the framework of health policy programs and the conditions for their implementation in the field of prevention of tobacco (nicotine) addiction.
Preparation of opinions on draft health policy programs of local government units:
- "Health Policy Program of the City of Skarżysko-Kamienna for 2023-2025 in the field of medical rehabilitation",
- "Health policy program in support of infertility treatment by in vitro fertilization - in vitro for residents of the Municipality of Zhukowice in 2023-2026".
Preparation of an opinion on the inclusion in reimbursement of drugs containing the active substances listed below in the indication: hypertension in adults, in cases other than those specified in the SmPC in the reimbursement availability category: available at the pharmacy by prescription:
- amlodipinum + valsartanum
- amlodipinum + valsartanum + hydrochlorothiazidum
- candesartanum + hydrochlorothiazidum
- candesartanum + amlodipinum
- indapamidum + amlodipinum
- lisinoprilum + amlodipinum
- lisinoprilum + hydrochlorothiazidum
- losartanum + amlodipinum
- losartanum + hydrochlorothiazidum
- perindoprilum + amlodipinum
- perindoprilum + indapamidum
- ramiprilum + amlodipinum
- ramiprilum + felodipinum
- ramiprilum + hydrochlorothiazidum
- telmisartanum + amlodipinum
- telmisartanum + hydrochlorothiazidum
- telmisartanum + indapamidum
- valsartanum + hydrochlorothiazidum.
Source: AOTMiT
